Cotización Akcea Therapeutics - AKCA | ADVFN

US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Akcea Therapeutics Inc (AKCA) Cotización

Akcea Therapeutics Inc (AKCA)

18.17

0.00

( 0.00% )

Actualizado: 18:00:00

Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Último Precio

18.17

Postura de Compra

18.08

Postura de Venta

19.00

Volume Operado de la Acción

-

0.00 Rango del Día 0.00

0.00 Rango de 52 semanas 0.00

Precio Anterior

18.17

Precio de Apertura

-

Hora

Última hora de negociación

-

Volumen promedio (3 m)

-

Volumen financiero

-

Precio Promedio Ponderado

-

Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product

Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif., Oct...

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif., Oct. 12...

WAYLIVRA▼® (volanesorsen), the First & Only Therapy for FCS, an Ultra-Rare & Life-Threatening Condition, to Be Available o...

National Institute for Health and Care Excellence (NICE) issues a positive recommendation for volanesorsen to treat adults with Familial Chylomicronaemia Syndrome (FCS) Akcea Therapeutics UK...

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics - Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash - Transaction...

Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020

Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020 Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant...

Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020

Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020 Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent...

Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020

Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020 Late-breaking presentation to focus on efficacy and safety data of vupanorsen in...

Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020

Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020 Data presentation will highlight efficacy, safety and tolerability of...

Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany

Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in...

Akcea Reports Financial Results and Highlights for Second Quarter 2020

Akcea Reports Financial Results and Highlights for Second Quarter 2020 Global Net Product Revenues of $16 Million, an Increase of 66% Year-Over-Year Achieved Pricing and Reimbursement Across Key...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
LAESSEALSQ Corporation	US$ 1.875 (63.04%)	229.18M
TRVITrevi Therapeutics Inc	US$ 3.965 (59.24%)	59.18M
PALIPalisade Bio Inc	US$ 2.18 (55.71%)	61.71M
GOEVCanoo Inc	US$ 0.1981 (52.38%)	896.81M
LNKSLinkers Industries Ltd	US$ 5.905 (38.94%)	844.07k
SPGCSacks Parente Golf Inc	US$ 0.3605 (-74.25%)	26.18M
KROSKeros Therapeutics Inc	US$ 18.12 (-73.61%)	12.1M
SFHGSamfine Creation Holdings Group Ltd	US$ 1.17 (-61.64%)	6.28M
TFFPTFF Pharmaceuticals Inc	US$ 0.0713 (-56.18%)	3.78M
BCTXBriaCell Therapeutics Corporation	US$ 0.662 (-39.82%)	6.68M
GOEVCanoo Inc	US$ 0.1979 (52.23%)	896.22M
LAESSEALSQ Corporation	US$ 1.8709 (62.69%)	223.06M
CDTConduit Pharmaceuticals Inc	US$ 0.0797 (-9.74%)	111.18M
RGTIRigetti Computing Inc	US$ 6.7012 (-9.20%)	110.22M
NVDANVIDIA Corporation	US$ 137.74 (-1.13%)	104.87M

Sidney

Sidney 7 años hace

Any thoughts on why so low today?

Thoro

Thoro 7 años hace

So Volatile. Any thoughts on why the big plunge today?

Rodney213

Rodney213 7 años hace

Like how clean the board is .Some heavy price target coverage today

dinosaurbob

dinosaurbob 7 años hace

Dropped heavy yesterday but bounced back some today. I am still up 17%, so I am not complaining.

Thoro

Thoro 7 años hace

This is a volatile stock. Its finding its legs.

dinosaurbob

dinosaurbob 7 años hace

Closed at $15.43 today up 47 cents.

dinosaurbob

dinosaurbob 7 años hace

Back up $1.02 today. This stock is like riding a roller coaster. Up one day and down the next. And big drops and rises too.

dinosaurbob

dinosaurbob 7 años hace

WTH happened today? Down $1.52!

dinosaurbob

dinosaurbob 7 años hace

Closed up 40 cents at $14.88

dinosaurbob

dinosaurbob 7 años hace

It was up big earlier but steadily dropping now. Still up 14 cents at 2:45 EST

Thoro

Thoro 7 años hace

AKCA, Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency

https://ih.advfn.com/p.php?pid=nmona&article=75321782

dinosaurbob

dinosaurbob 7 años hace

Closed up at $14.48 (5.16%). Nice!

Thoro

Thoro 7 años hace

I know it dropped, but I like when it tests higher.

dinosaurbob

dinosaurbob 7 años hace

Yes, but it dropped to $13.77. I still believe in it though.

Thoro

Thoro 7 años hace

AKCA $16.30 looked great today!

dinosaurbob

dinosaurbob 7 años hace

I bought in at 9.88 and then doubled my portfolio Friday at $13.00. I see this over $20.00 by October!

Thoro

Thoro 7 años hace

AKCA

IPO doing great first 5 days of trading.

Thoro

Thoro 7 años hace

AKCA

#MARKET NEWS
JULY 14, 2017 / 12:12 PM / 3 DAYS AGO
BRIEF-Akcea Therapeutics Inc shares open at $8.13 in debut vs IPO price of $8/share

http://www.reuters.com/article/brief-akcea-therapeutics-inc-shares-open-idUSFWN1K50CZ

Thoro

Thoro 7 años hace

AKCA

#MARKET NEWS
JULY 13, 2017 / 8:30 PM / 4 DAYS AGO

BRIEF-Akcea Therapeutics says public offering of 15.6 mln common shares priced at $8 per share

http://www.reuters.com/article/brief-akcea-therapeutics-says-public-off-idUSASA09X2O

Akcea Therapeutics

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones